Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.60 |
| ▸ | FLT4 | P35916 | 8/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 7/20 | 0.58 |
| ▸ | CSF1R | P07333 | 4/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | KIF5B | P33176 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24262961 | 0.89 | KDR (0.58) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL29397934 | 0.85 | KDR (0.58) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL22169946 | 0.85 | KDR (0.58) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL22164824 | 0.84 | PDGFRB (0.64) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL1097832 | 0.82 | PDGFRB (0.67) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL20771410 | 0.82 | PDGFRB (0.67) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL22165252 | 0.82 | PDGFRB (0.64) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL5177524 | 0.81 | PDGFRB (0.66) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL1099346 | 0.81 | PDGFRB (0.66) | KDRPDGFRBFLT4PDGFRAFLT3 | |
| SCHEMBL22165149 | 0.81 | KIT (0.52) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-02-24 | — | — | US | disclosed |
| EP-3902787-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020140001-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140001-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | KDR 3712/4885PDGFRB 2961/4885FLT4 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.